26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206, and 8843 molecules and uses therefor

US7485308B2 · kind B2 · utility

Assignee

• Millennium Pharmaceuticals, Inc. · US

Inventors

• Rachel Meyers · Newton, US
• Kyle MacBeth · Boston, US
• Rory Curtis · Southborough, US
• Laura Rudolph-Owen · Medford, US
• Nadine Weich · Brookline, US
• Peter Olandt · Newton, US
• Fong-Ying Tsai · Newton, US
• Rosana Kapeller-Libermann · Sharon, US
• Joseph Carroll · Cambridge, US

Key dates

• Filing date: Jul 26, 2006
• Grant date: Feb 3, 2009
• Expiry date: Jul 26, 2026

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10T436/143333
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.